Clinical trials: Locoregionally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma, Children
Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
1. To see the effect if a combination of induction chemotherapy followed by chemoradiotherapy works in treating children with advanced nasopharyngeal carcinoma(NPC).
- Trial name
- NCT03020329
- Testing
- Paclitaxel liposome, Cisplatin, 5-fu
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensified chemoradiotherapy sparing concurrent…
- Trial name
- DIAMOND (NCT04907370)
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80mg/m2)
- Where
- 12 sites in China
- Volunteers
- 532 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction…
- Trial name
- NCT04456322
- Testing
- RT plus Nimotuzumab, RT plus Cisplatin
- Where
- China
- Volunteers
- 381 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.
- Trial name
- NCT01712919
- Testing
- Intensity-modulated radiotherapy, Concurrent chemotherapy with paclitaxel and nedaplatin, Cetuximab
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
- Trial name
- NCT06749899
- Testing
- QL1706, Gemcitabine, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 580 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Adebrelimab and Chemoradiotherapy in High-risk LANPC
This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
- Trial name
- NCT06349889
- Testing
- Adebrelimab
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy plus adjuvant chemotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced NPC, in order to evaluate the value of adjuvant…
- Trial name
- NCT00677118
- Testing
- Cisplatin,fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 506 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma
This study aims to evaluate a personalized approach for treating patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- RAIRI-NPC (NCT07590024)
- Testing
- PD-1 inhibitor, Capecitabine
- Where
- China
- Volunteers
- 651 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and Penpulimab ± Anlotinib in neoadjuvant therapy combined with Penpulimab in adjuvant therapy of locoregionally advanced…
- Trial name
- NCT05193617
- Testing
- GP+Penpulimab+Anlotinib, GP+Penpulimab
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma
This trial plans to enroll 40 patients with stage III-IVA (AJCC 8th, except T3N0-1 or T4N0) locoregionally-advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT03619824
- Testing
- Sintilimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC
Concurrent cisplatin-based chemotherapy plus radiotherapy increased the risk of treatment-related death and severe acute toxicity.
- Trial name
- NPC (NCT01854203)
- Testing
- Inductive chemotherapy + concurrent cisplatin and IMRT, Inductive chemotherapy + IMRT
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Cisplatin, Carboplatin
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare cisplatin-based with carboplatin-based chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in order to confirm the value of carboplatin-based…
- Conditions
- Cisplatin, Carboplatin, NPC
- Trial name
- NCT03919552
- Testing
- Docetaxel,Carboplatin, Docetaxel,Cisplatin, Carboplatin-based concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 482 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy with becotatug vedotin (MRG003) plus pucotenlimab, followed by treatment allocation based on…
- Trial name
- NCT07524413
- Testing
- Becotatug Vedotin, Pucotenlimab, Intensity-Modulated Radiotherapy
- Volunteers
- 298 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Malnutrition
Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients
This is an prospective，open-label, none-interventional, observational， multicenter phase II clinical trial. The purpose of this study is to observe the effect of neoadjuvant chemotherapy followed by concurrent chemoradiation…
- Trial name
- NCT02575547
- Testing
- cisplatin and docetaxel
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Zhao Chong
Nasopharyngeal Carcinoma
The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Two Phase Ⅲ trials (TAX323 and TAX324) showed induction chemotherapy adding docetaxel to cisplatin plus fluorouracil (TPF) could significant improve survival in head and neck cancer, and a Phase Ⅱ trial from Hong Kong by Hui and…
- Trial name
- NCT02096380
- Testing
- One cycle TPF induction chemotherapy for NPC, Three cycles TPF induction chemotherapy for NPC
- Volunteers
- 120 people
- Sponsor
- First People's Hospital of Foshan
Nasopharyngeal Carcinoma
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal…
- Trial name
- NCT05211232
- Testing
- Tislelizumab
- Where
- 4 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, De-escalation Therapy
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
This prospective trial aims to enroll patients with high-risk stage III-IVA (AJCC 8th, except T3N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06092957
- Testing
- Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Sun Yat-sen University
Malignant Neoplasm of Other Specified Site of Nasopharynx
Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients
To investigate whether the additional induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) was able to improve overall survival (OS) and disease-free survival (DFS), and to clarify if stage-specified…
- Trial name
- NCT02604472
- Testing
- CCRT, IC+CCRT
- Volunteers
- 12,206 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma
Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03932266
- Testing
- Endostar, Cisplatin, Docetaxel
- Volunteers
- 73 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Nasopharyngeal Carcinoma
Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus concurrent chemoradiotherapy with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC)…
- Trial name
- NCT01417390
- Testing
- Drug: Gemcitabine and cisplatin, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First People's Hospital of Foshan